Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.32%
SPX
-0.01%
IXIC
+0.05%
FTSE
+0.22%
N225
-0.21%
AXJO
+1.37%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

INCY is now overvalued and could go down -34%

Jul 13, 2025, 12:00 PM
-1.11%
What does INCY do
Yte is a Wilmington, Delaware-based biopharmaceutical company with 2,524 employees, focusing on hematology/oncology and inflammation/autoimmunity therapeutic areas. Its product portfolio includes JAKAFI, MONJUVI, and PEMAZYRE, among others.
Based on our analysis, YTE has received an overvalued rating of 1 out of 5 stars from Cashu, primarily driven by its financial ratios that significantly exceed industry norms. One of the most striking metrics is the Price-to-Earnings (PE) Ratio, which stands at 624.21, compared to the sector average of 14.18. A high PE ratio suggests that investors are paying substantially more for each dollar of earnings, indicating that the stock may be overpriced relative to its earnings potential. Additionally, the Price-to-Book (PB) Ratio for YTE is 3.86, while the sector average is 2.71. This ratio indicates how much investors are willing to pay for each dollar of net assets. A higher PB ratio could imply that investors have unrealistic expectations of the company's future growth, which may not materialize. Furthermore, YTE's profitability metrics, such as the Net Profit Margin of 0.77, contrast sharply with the sector’s average of -137.57. While a positive margin indicates that YTE is generating profits, the number is not indicative of strong financial health when compared to the broader industry context. In terms of efficiency, the Return on Equity (ROE) Ratio is 0.95, compared to the sector’s -76.41. While YTE is generating returns on shareholders' equity, the low figure relative to the sector suggests limited effectiveness in utilizing equity capital. Overall, YTE's inflated ratios signal a potential misalignment between its market valuation and actual financial performance. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!